J&J has its eye on Ollin: $3.4bn vision-loss biotech deal in the works
Finimize, citing the Financial Times, reports that Johnson & Johnson is in talks to buy Texas-based Ollin Biosciences for up to $3.4 billion. The deal would pay $2.2 billion in cash upfront, with up to $1.2 billion more tied to milestones such as trial results, regulatory approval and sales targets. The prize is OLN324, an experimental drug in late-stage studies for diabetic macular edema and wet age-related macular degeneration, two common causes of vision loss.
From finimize.com's report.
Why it matters: If completed, J&J would gain an experimental late-stage drug for two common causes of vision loss, signaling big-pharma interest in eye treatments; patients could benefit if trials and regulators approve it.
Comments
No comments yet.